MedTrace Logo

Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation

NCT03620760 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2036

Last updated 2018-12-24

No results posted yet for this study

Summary

The study is to evaluate efficacy and safety of low dose of ticagrelor therapy for Chinese unstable angina patients treated with non-urgent coronary stent implantation, to examine whether lower dose ticagrelor (45 mg twice-daily) is not inferior to standard dose (90 mg twice-daily) for the prevention of major adverse cardiovascular and cerebrovascular events, as well as will reduce the incidence of bleeding during long-term treatment.

Conditions

  • Unstable Angina Pectoris
  • Coronary Stent Implantation

Interventions

DRUG

Ticagrelor 90 mg

Ticagrelor (AZD6140) 90 mg twice daily dose

DRUG

Ticagrelor 45 mg

Ticagrelor (AZD6140) 45 mg twice daily dose

DRUG

Aspirin

Aspirin 100 mg once daily dose

Sponsors & Collaborators

  • Xiaofan Wu

    lead OTHER

Principal Investigators

  • Xiaofan Wu · Beijing Anzhen Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-07
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03620760 on ClinicalTrials.gov